Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
2.

Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.

Soyka M.

Expert Opin Drug Deliv. 2012 Nov;9(11):1409-17. doi: 10.1517/17425247.2012.729574. Epub 2012 Sep 26. Review.

PMID:
23013384
3.

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Mattick RP, Breen C, Kimber J, Davoli M.

Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. Review.

PMID:
24500948
4.

Opioid dependence treatment, including buprenorphine/naloxone.

Raisch DW, Fye CL, Boardman KD, Sather MR.

Ann Pharmacother. 2002 Feb;36(2):312-21. Review.

PMID:
11847954
5.

Buprenorphine implants in medical treatment of opioid addiction.

Chavoustie S, Frost M, Snyder O, Owen J, Darwish M, Dammerman R, Sanjurjo V.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):799-807. doi: 10.1080/17512433.2017.1336434. Epub 2017 Jun 21. Review.

PMID:
28571505
6.

Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.

Soyka M.

Expert Opin Drug Deliv. 2015 Feb;12(2):339-47. doi: 10.1517/17425247.2014.953479. Epub 2014 Aug 25. Review.

PMID:
25156759
7.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
8.

Buprenorphine: how to use it right.

Johnson RE, Strain EC, Amass L.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77. Review.

PMID:
12738351
9.

Spotlight on buprenorphine/naloxone in the treatment of opioid dependence.

Orman JS, Keating GM.

CNS Drugs. 2009 Oct;23(10):899-902. doi: 10.2165/11203740-000000000-00000. Review.

PMID:
19739698
10.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
11.

Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.

Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A.

Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134. doi: 10.1177/2045125316681984. Epub 2016 Dec 19. Review.

12.

Buprenorphine dosing choices in specific populations: review of expert opinion.

Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N.

Expert Opin Pharmacother. 2016 Sep;17(13):1727-31. doi: 10.1080/14656566.2016.1209486. Epub 2016 Aug 2. Review.

PMID:
27376622
13.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Soyka M.

Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015. Review.

14.

New developments in managing opioid addiction: impact of a subdermal buprenorphine implant.

Itzoe M, Guarnieri M.

Drug Des Devel Ther. 2017 May 10;11:1429-1437. doi: 10.2147/DDDT.S109331. eCollection 2017. Review.

15.

Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K.

Subst Abuse Rehabil. 2011 Oct 28;2:181-8. doi: 10.2147/SAR.S22782. eCollection 2011. Review.

16.

Use of Buprenorphine in treatment of refractory depression-A review of current literature.

Stanciu CN, Glass OM, Penders TM.

Asian J Psychiatr. 2017 Apr;26:94-98. doi: 10.1016/j.ajp.2017.01.015. Epub 2017 Jan 27. Review.

PMID:
28483102

Supplemental Content

Support Center